Trials / Not Yet Recruiting
Not Yet RecruitingNCT07483554
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 389 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI343,Gemcitabine, Albumin-bound Paclitaxel | IBI343,Gemcitabine, Albumin-bound Paclitaxel intravenous infusion |
Timeline
- Start date
- 2026-03-25
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2026-03-19
- Last updated
- 2026-03-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07483554. Inclusion in this directory is not an endorsement.